Key Points
- Biotech's iShares ETF (IBB) experienced a near 4% upswing on the year's first trading day, outshining struggling sectors.
- The IBB ETF now faces critical resistance at $138 after a robust three-month climb.
- AMGN, VRTX, and GILD, the top holdings in the ETF, significantly impact the sector's direction based on their individual performances.
- 5 stocks we like better than iShares Biotechnology ETF
Upgrade Now
This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.
Already have an account? Log in here.
Before you consider iShares Biotechnology ETF, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iShares Biotechnology ETF wasn't on the list.
While iShares Biotechnology ETF currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
